Trials / Completed
CompletedNCT01857206
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,055 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 4 Years – 17 Years
- Healthy volunteers
- Accepted
Summary
Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mammalian cell based flu vaccine | |
| BIOLOGICAL | Egg based flu vaccine |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2013-05-20
- Last updated
- 2014-12-05
- Results posted
- 2014-11-03
Locations
34 sites across 5 countries: United States, Australia, New Zealand, Philippines, Thailand
Source: ClinicalTrials.gov record NCT01857206. Inclusion in this directory is not an endorsement.